| Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline MJ Sonneveld, V Rijckborst, CAB Boucher, BE Hansen, HLA Janssen Hepatology 52 (4), 1251-1257, 2010 | 411 | 2010 |
| Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels MJ Sonneveld, BE Hansen, T Piratvisuth, JD Jia, S Zeuzem, E Gane, ... Hepatology 58 (3), 872-880, 2013 | 291 | 2013 |
| Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians P Arends, MJ Sonneveld, R Zoutendijk, I Carey, A Brown, M Fasano, ... Gut 64 (8), 1289-1295, 2015 | 227 | 2015 |
| Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B MJ Sonneveld, VWS Wong, AM Woltman, GLH Wong, Y Cakaloglu, ... Gastroenterology 142 (3), 513-520. e1, 2012 | 224 | 2012 |
| Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis R Zoutendijk, JGP Reijnders, F Zoulim, A Brown, DJ Mutimer, K Deterding, ... Gut 62 (5), 760-765, 2013 | 219 | 2013 |
| Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) WP Brouwer, Q Xie, MJ Sonneveld, N Zhang, Q Zhang, F Tabak, ... Hepatology 61 (5), 1512-1522, 2015 | 210 | 2015 |
| Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir JGP Reijnders, V Rijckborst, MJ Sonneveld, SMJ Scherbeijn, ... Journal of hepatology 54 (3), 449-454, 2011 | 210 | 2011 |
| Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen‐positive chronic hepatitis B MJ Sonneveld, V Rijckborst, S Zeuzem, EJ Heathcote, K Simon, ... Hepatology 56 (1), 67-75, 2012 | 104 | 2012 |
| Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte‐derived micro RNA‐122 AJ van der Meer, WRR Farid, MJ Sonneveld, PE de Ruiter, A Boonstra, ... Journal of viral hepatitis 20 (3), 158-166, 2013 | 103 | 2013 |
| Probability of HBsAg loss after nucleo (s) tide analogue withdrawal depends on HBV genotype and viral antigen levels MJ Sonneveld, SM Chiu, JY Park, SM Brakenhoff, A Kaewdech, WK Seto, ... Journal of hepatology 76 (5), 1042-1050, 2022 | 92 | 2022 |
| Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV R Zoutendijk, HL Zaaijer, TEMS de Vries-Sluijs, JGP Reijnders, ... The Journal of infectious diseases 206 (6), 974-980, 2012 | 92 | 2012 |
| Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? HLA Janssen, MJ Sonneveld, MR Brunetto Gut 61 (5), 641-645, 2012 | 91 | 2012 |
| A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B MJ Sonneveld, V Rijckborst, CAB Boucher, L Zwang, MFC Beersma, ... Journal of clinical virology 51 (3), 175-178, 2011 | 89 | 2011 |
| Hepatitis B surface antigen monitoring and management of chronic hepatitis B MJ Sonneveld, R Zoutendijk, HLA Janssen Journal of viral hepatitis 18 (7), 449-457, 2011 | 89 | 2011 |
| Off-therapy response after nucleos (t) ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study) G Hirode, HSJ Choi, CH Chen, TH Su, WK Seto, S Van Hees, ... Gastroenterology 162 (3), 757-771. e4, 2022 | 85 | 2022 |
| Durable Hepatitis B Surface Antigen Decline in Hepatitis BE Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV … MJ Sonneveld, V Rijckborst, Y Cakaloglu, K Simon, EJ Heathcote, ... Antiviral therapy 17 (1), 9-17, 2012 | 78 | 2012 |
| Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B LA van Kleef, HSJ Choi, WP Brouwer, BE Hansen, K Patel, RA de Man, ... Jhep Reports 3 (5), 100350, 2021 | 71 | 2021 |
| Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B MJ Sonneveld, P Arends, A Boonstra, BE Hansen, HLA Janssen Journal of hepatology 58 (5), 898-903, 2013 | 68 | 2013 |
| Prediction of sustained response after nucleo (s) tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE) MJ Sonneveld, JY Park, A Kaewdech, WK Seto, Y Tanaka, I Carey, ... Clinical Gastroenterology and Hepatology 20 (4), e784-e793, 2022 | 67 | 2022 |
| Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study MJ Sonneveld, WP Brouwer, HLY Chan, T Piratvisuth, JD Jia, S Zeuzem, ... The Lancet Gastroenterology & Hepatology 4 (7), 538-544, 2019 | 66 | 2019 |
